📰 Amanda Sheldon News
Amanda Sheldon News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Amanda Sheldon. Real-time updates on events, politics, business and more.
April 30, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
April 29, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 -- Arcutis Biotherapeutics, Inc. , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today...
April 10, 2024
Industry veteran with over 40 years of experience in finance, investment management, and investment bankingWESTLAKE VILLAGE, Calif., April 10, 2024 -- Arcutis Biotherapeutics, Inc. , a...
April 5, 2024
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
March 11, 2024
Industry veteran with over 25 years’ experience will continue to advance the company culture and grow the capabilities of Arcutis’ workforce WESTLAKE VILLAGE, Calif., March 11, 2024 -- Arcutis...
March 10, 2024
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children...
March 10, 2024
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement ...
March 10, 2024
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children...
March 9, 2024
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis...
February 29, 2024
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,